On this page

TechneLite

Technetium Tc99m Generator · Injection, Solution

Prescription NDA RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information.

Overview

Brand name
TechneLite
Generic name
Technetium Tc99m Generator
Dosage form
Injection, Solution
Route
Intravenous
Marketing category
NDA · NDA
Labeler
Lantheus Medical Imaging, Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
2
Packages
28
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Technetium Tc-99M Sodium Pertechnetate 250 mCi/mL — View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Injection, Solution
Route of administration
Intravenous
Presentations
30

Regulatory status

Source: Drugs@FDANDC Directory
Application number
017771
Application type
NDA · New Drug Application
Approval date
November 16, 1976
Sponsor
SHINE
Products on application
2
Submissions recorded
30
Products approved under application 017771.
Product Trade name Form Strength Ingredient Status TE Flags
017771-001 TECHNELITE SOLUTION TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR Discontinued —
017771-002 TECHNELITE SOLUTION TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR Prescription — RLD RS

Therapeutic equivalence

Source: Orange Book
TE code
—
Reference Listed Drug
Yes
Reference Standard
Yes

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 017771.
Type No. Action Status Date Review
Supplement 44 Labeling Approved January 20, 2023 Standard
Supplement 40 Manufacturing (CMC) Approved November 15, 2016 Standard
Supplement 38 Manufacturing (CMC) Approved February 12, 2016 Standard
Supplement 39 Manufacturing (CMC) Approved August 27, 2015 Standard
Supplement 36 Manufacturing (CMC) Approved February 9, 2015 Standard
Supplement 35 Labeling Approved February 12, 2014 Standard
Supplement 34 Manufacturing (CMC) Approved November 16, 2012 Standard
Supplement 25 Manufacturing (CMC) Approved March 25, 2009 Standard
Supplement 24 Manufacturing (CMC) Approved December 7, 2007 Standard
Supplement 23 Manufacturing (CMC) Approved September 2, 2004 Standard
Supplement 22 Manufacturing (CMC) Approved December 5, 2001 Standard
Supplement 21 Manufacturing (CMC) Approved December 6, 2000 Standard
Supplement 19 Labeling Approved August 11, 2000 Standard
Supplement 20 Manufacturing (CMC) Approved February 29, 2000 Standard
Supplement 18 Manufacturing (CMC) Approved February 4, 1998 Standard
Supplement 17 Manufacturing (CMC) Approved December 15, 1997 Standard
Supplement 16 Manufacturing (CMC) Approved November 5, 1997 Standard
Supplement 15 Manufacturing (CMC) Approved April 5, 1996 Standard
Supplement 14 Manufacturing (CMC) Approved January 24, 1996 Standard
Supplement 13 Manufacturing (CMC) Approved January 11, 1996 Standard
Supplement 12 Manufacturing (CMC) Approved May 23, 1995 Standard
Supplement 11 Manufacturing (CMC) Approved August 12, 1993 Standard
Supplement 10 Manufacturing (CMC) Approved January 12, 1993 Standard
Supplement 9 Labeling Approved April 29, 1985 —
Supplement 8 Manufacturing (CMC) Approved May 13, 1983 Standard
Supplement 7 Manufacturing (CMC) Approved April 18, 1983 Standard
Supplement 5 Labeling Approved November 21, 1978 —
Supplement 1 Manufacturing (CMC) Approved October 11, 1978 Standard
Supplement 2 Manufacturing (CMC) Approved June 7, 1978 Standard
Original application 1 Type 5 - New Formulation or New Manufacturer Approved November 16, 1976 Standard

Review documents

  • 0 · Supplement · January 23, 2023
  • 0 · Supplement · January 23, 2023
  • 0 · Supplement · February 13, 2014
  • 0 · Supplement · February 12, 2014

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20241101). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20241101

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: The Technelite generator is a source of sodium pertechnetate Tc 99m for use in the preparation of FDA-approved diagnostic radiopharmaceuticals, as described in the labeling of these diagnostic radiopharmaceutical kits. Sodium Pertechnetate Tc 99m Injection is used IN ADULTS as an agent for: Thyroid Imaging Salivary Gland Imaging Urinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux. Nasolacrimal Drainage System Imaging Sodium Pertechnetate Tc 99m Injection is used IN CHILDREN as an agent for: Thyroid Imaging Urinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: Sodium Pertechnetate Tc 99m Injection is usually administered by intravascular injection. For imaging the urinary bladder and ureters (direct isotopic cystography), the Sodium Pertechnetate Tc 99m Injection is administered by direct instillation aseptically into the bladder via a urethral catheter, following which the catheter is flushed with approximately 200 mL of 0.9% Sodium Chloride Injection, USP directly into the bladder. The dosage employed varies with each diagnostic procedure. When imaging the nasolacrimal drainage system, instill the Sodium Pertechnetate Tc 99m Injection by the use of a device such as a micropipette or similar method which will ensure the accuracy of the dose. The suggested dose range employed for various diagnostic indications in the average ADULT PATIENT (70kg) is: Vesico-ureteral Imaging 18.5 to 37MBq (0.5 to 1mCi) Thyroid Gland Imaging 37 to 370MBq (1 to 10mCi) Salivary Gland Imaging 37 to 185MBq (1 to 5mCi) Nasolacrimal Drainage System Maximum 3.7MBq (100μCi) The recommended dosage range in PEDIATRIC PATIENTS is: Vesico-ureteral Imaging 18.5 to 37MBq (0.5 to 1mCi) Thyroid Gland Imaging 2.22 to 2.96MBq (60 to 80μCi)/kg body weight The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration of the dose. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. The solution to be administered as the patient dose should be clear and contain no particulate matter. Do not use an eluate of the TECHNELITE ® , Technetium Tc 99m Generator later than one (1) working day after elution (12 hours). Radiation Dosimetry The estimated absorbed radiation doses to an average ADULT and Pediatric patient from an intravenous injection of a maximum dose of 1110MBq (30 millicuries) of Sodium Pertechnetate Tc 99m Injection distributed uniformly in the total body are shown in Tables 5 and 6. Table 5. Adult Absorbed Radiation Doses (mGy) from Intravenous Injection Organ Absorbed Radiation Dose (mGy) for a 1110 MBq (30mCi) dose To obtain radiation absorbed dose in rads (30 mCi dose) from the above table, divide individual organ values by a factor of 10 (does not apply for effective dose). Adrenals 4.1 Urinary Bladder Wall 20 Bone Surfaces 6.2 Brain 2.2 Breasts 2 Gallbladder Wall 8.3 Stomach Wall 29 Small Intestine 18 ULI Wall 63 LLI Wall 23 Heart Wall 3.5 Kidneys 6 Liver 4.7 Lungs 2.9 Muscle 3.6 Ovaries 11 Pancreas 6.3 Red Marrow 4.1 Skin 2 Spleen 4.8 Testes 3.1 Thymus 2.7 Thyroid 24 Uterus 9 Remaining Tissues 3.9 Effective Dose (mSv) 14 Table 6. Pediatric Absorbed Radiation Doses (mGy) from Intravenous Injection Age 15 years 10 years 5 years 1 year To obtain radiation absorbed dose in rads (30 mCi dose) from the above table, divide individual organ values by a factor of 10 (does not apply for effective dose). Administered activity in MBq (mCi) 1110 (30) 740 (20) 555 (15) 370 (10) Organ Adrenals 5.3 5.4 6.2 7.1 Urinary Bladder Wall 26 22 18 22 Bone Surfaces 7.6 7.5 8.1 10 Brain 2.8 3.1 3.7 4.5 Breasts 2.6 2.6 3.2 4.1 Gallbladder Wall 11 12 13 13 Stomach Wall 38 36 43 59 Small Intestine 22 23 26 30 ULI Wall 81 89 110 140 LLI Wall 31 33 40 48 Heart Wall 4.5 4.6 5.2 6.4 Kidneys 7.2 6.9 7.8 8.5 Liver 6 6.7 8 9.1 Lungs 3.8 3.8 4.4 5.3 Muscle 4.5 4.5 5 6 Ovaries 14 13 14 17 Pancreas 8.1 8.2 8.9 10 Red Marrow 5.1 5 5.2 6 Skin 2.5 2.6 3.2 3.8 Spleen 6 6 6.7 7.8 Testes 4.1 4.3 4.9 6 Thymus 3.6 3.5 4.2 5.3 Thyroid 40 41 67 81 Uterus 11 11 12 14 Remaining Tissues 4.8 4.8 5.4 6.4 Effective Dose (mSv) 19 19 23 29 The estimated absorbed radiation doses to an average ADULT from the instillation of Sodium Pertechnetate Tc 99m Injection for imaging the nasolacrimal drainage system are shown in Table 7. Table 7. Absorbed Radiation Dose from Dacryoscintigraphy Using Sodium Pertechnetate Tc 99m Absorbed Dose Target Organ mGy/ 3.7MBq (rad/ 100μCi) * Assuming n …

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS: None known.

WARNINGS: Radiation risks associated with the use of Sodium Pertechnetate Tc 99m Injection are greater in children than in adults and, in general, the younger the child, the greater the risk owing to greater absorbed radiation doses and longer life-expectancy. These greater risks should be taken firmly into account in all benefit-risk assessments involving children. Long-term cumulative radiation exposure may be associated with an increased risk of cancer.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS: Allergic reactions including anaphylaxis have been reported infrequently following the administration of Sodium Pertechnetate Tc 99m Injection.

Description

openFDA Drug Labeling

DESCRIPTION: Sodium Pertechnetate Tc 99m Injection, as eluted according to the elution instructions with Lantheus Medical Imaging, Inc. TECHNELITE ® , Technetium Tc 99m Generator, is in 0.9% Sodium Chloride Injection, USP as a sterile, non-pyrogenic, diagnostic radiopharmaceutical suitable for intravenous injection and direct instillation. The pH is 4.5-7.5. The eluate should be clear, colorless, and free from visible foreign material. Each eluate of the TECHNELITE ® , Technetium Tc 99m Generator should not contain more than 0.0056MBq (0.15 microcuries) of Molybdenum Mo99 per 37MBq (1 millicurie) of Technetium Tc 99m per administered dose at the time of administration, and not more than 10 micrograms of aluminum per milliliter of the Technetium Tc 99m Generator eluate, both of which must be determined by the user before administration. Since the eluate does not contain an antimicrobial agent, it should not be used later than one (1) working day after the elution (12 hours). Lantheus Medical Imaging, Inc. TECHNELITE ® , Technetium Tc 99m Generator consists of a column containing uranium fission produced Molybdenum Mo99 adsorbed on alumina. The terminally sterilized and sealed column is enclosed in a lead shield; the shield and other components are sealed in a cylindrical plastic container with an attached handle. Built into the top surface are two recessed wells marked SALINE CHARGE and COLLECT. Needles protruding from these two wells accommodate supplied sterile eluant charge vials and sterile eluate collection vials. The eluting solvent consists of 0.9% Sodium Chloride Injection, USP, prepacked into septum-sealed vials, to make the solution isotonic. The eluate collection vial is evacuated, sterile and non-pyrogenic. A sterile 0.22 micrometer bacteriological filter is incorporated between the column outlet and the collection vials. During and subsequent to elution, the eluate collection vial should be kept in a radiation shield. The Generator is shipped with a silicone needle seal over the charge needle and a vented needle cover over the collect needle. A sterile collect needle seal is supplied for the customer to aseptically reseal the collect needle after each elution. Physical Characteristics Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours. 1 Photons that are useful for imaging studies are listed in Table 1. Table 1. Principal Radiation Emission Data - Technetium Tc 99m Radiation Mean %/Disintegration Mean Energy (keV) Gamma-2 89.07 140.5 External Radiation The specific gamma ray constant for Technetium Tc 99m is 5.4 microcoulombs/Kg-MBq-hr (0.795 R/mCi-hr) at 1cm. The first half-value thickness is 0.023cm of lead (Pb). To facilitate control of radiation exposure from millicurie amounts of Technetium Tc 99m, for example, the use of a 0.27 cm thick standard radiation elution lead shield will attenuate the radiation emitted by a factor of about 1000. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of lead is shown in Table 2. NOTE : Because the generator is well contained and essentially dry, there is little likelihood of contamination due to damage in transit. Table 2. Radiation Attenuation of Technetium Tc 99m by Lead Shielding Shield Thickness lead (Pb) cm Coefficient of Attenuation 0.023 0.5 0.09 10 -1 0.18 10 -2 0.27 10 -3 0.33 10 -4 Molybdenum Mo99 decays to Technetium Tc 99m with a Molybdenum Mo99 half-life of 66 hours. This means that only 78% of the activity remains after 24 hours; 60% remains after 48 hours, etc. (see Table 3). All units have a minimum of 38 mm, 1.5 inches (~ 6 half-value layers) of lead surrounding the activity. (See Table 3.) Table 3. Molybdenum Mo99 Decay Chart Half-Life 66.0 Hours Days Percent Remaining Days Percent Remaining 0 100 10 8 1 78 11 6 2 60 12 5 3 47 13 4 4 37 14 3 5 28 15 2 6 22 20 0.6 7 17 25 0.2 8 13 30 0.05 9 10 The physical decay characteris …

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED: Lantheus Medical Imaging TechneLite ® , (Technetium Tc 99m Generator) for the Production of Sodium Pertechnetate Tc 99m Injection is supplied in a multi-dose container and is available in the following quantities of radioactivity of Mo99 on the calibration date (date of manufacture) as specified on the product lot identification label affixed to the generator: Table 9 Available Quantities of Radioactivity High Enriched Uranium (HEU) Low Enriched Uranium (LEU) NDC # GBq of Mo99 Ci of Mo99 NDC # GBq of Mo99 Ci of Mo99 11994-090-36 37.0 1 11994-091-36 37.0 1 11994-090-73 74.0 2 11994-091-73 74.0 2 11994-090-92 92.5 2.5 11994-091-92 92.5 2.5 11994-090-01 111.0 3 11994-091-01 111.0 3 11994-090-03 148.0 4 11994-091-03 148.0 4 11994-090-04 166.5 4.5 11994-091-04 166.5 4.5 11994-090-05 185.0 5 11994-091-05 185.0 5 11994-090-06 222.0 6 11994-091-06 222.0 6 11994-090-07 277.5 7.5 11994-091-07 277.5 7.5 11994-090-09 370.0 10 11994-091-09 370.0 10 11994-090-10 462.5 12.5 11994-091-10 462.5 12.5 11994-090-11 555.0 15 11994-091-11 555.0 15 11994-090-12 666.0 18 11994-091-12 666.0 18 11994-090-13 740.0 20 11994-091-13 740.0 20 Each generator is supplied with the following standard components: Collect Needle Seal Eluant Charge Vials (may be supplied separately) Eluate Collection Vials (may be supplied separately) 1 Package Insert 6 Radiation Labels (Collection Vial) 6 Radiation Labels (Eluting Shield) First order generators are shipped with the following accessory components: 2 Eluting Shields Additional quantities of these components may be obtained at the customer's request.

Adverse event reports

Source: openFDA FAERS
0
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
11994-090-01 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-01) / 12 mL in 1 VIAL November 1, 1975
11994-090-03 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-03) / 16 mL in 1 VIAL November 1, 1975
11994-090-04 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-04) / 18 mL in 1 VIAL November 1, 1975
11994-090-05 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-05) / 20 mL in 1 VIAL November 1, 1975
11994-090-06 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-06) / 24 mL in 1 VIAL November 1, 1975
11994-090-07 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-07) / 30 mL in 1 VIAL November 1, 1975
11994-090-09 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-09) / 40 mL in 1 VIAL November 1, 1975
11994-090-10 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-10) / 50 mL in 1 VIAL November 1, 1975
11994-090-11 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-11) / 60 mL in 1 VIAL November 1, 1975
11994-090-12 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-12) / 72 mL in 1 VIAL November 1, 1975
11994-090-13 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-13) / 80 mL in 1 VIAL November 1, 1975
11994-090-36 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-36) / 4 mL in 1 VIAL November 1, 1975
11994-090-73 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-73) / 8 mL in 1 VIAL November 1, 1975
11994-090-92 11994-090 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-090-92) / 10 mL in 1 VIAL November 1, 1975
11994-091-01 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-01) / 12 mL in 1 VIAL September 28, 2010
11994-091-03 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-03) / 16 mL in 1 VIAL September 28, 2010
11994-091-04 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-04) / 18 mL in 1 VIAL September 28, 2010
11994-091-05 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-05) / 20 mL in 1 VIAL September 28, 2010
11994-091-06 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-06) / 24 mL in 1 VIAL September 28, 2010
11994-091-07 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-07) / 30 mL in 1 VIAL September 28, 2010
11994-091-09 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-09) / 40 mL in 1 VIAL September 28, 2010
11994-091-10 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-10) / 50 mL in 1 VIAL September 28, 2010
11994-091-11 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-11) / 60 mL in 1 VIAL September 28, 2010
11994-091-12 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-12) / 72 mL in 1 VIAL September 28, 2010
11994-091-13 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-13) / 80 mL in 1 VIAL September 28, 2010
11994-091-36 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-36) / 4 mL in 1 VIAL September 28, 2010
11994-091-73 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-73) / 8 mL in 1 VIAL September 28, 2010
11994-091-92 11994-091 Lantheus Medical Imaging, Inc. 1 VIAL in 1 CARTON (11994-091-92) / 10 mL in 1 VIAL September 28, 2010
11994-090 11994-090 Lantheus Medical Imaging, Inc. — November 1, 1975
11994-091 11994-091 Lantheus Medical Imaging, Inc. — November 1, 1975

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Drug Labeling FDA / NLM Prescribing information reproduced above

Generated September 25, 2026 · 9 sections on this page.